Pancreatic Cancer Defense Mechanism Identified in Study
Researchers found that specific cancer cells create shields that help tumors hide from the body's immune system.
Updated on Sept. 24, 2026 in Cancer
Live Poll
Are you confident that new cancer research breakthroughs will lead to better survival outcomes soon?
A study published on September 9, 2026, identified a subpopulation of pancreatic cancer cells that build immune-suppressing fibrin barriers. This shield blocks cancer-killing T cells and helps protect the tumor.
Why it matters
Pancreatic ductal adenocarcinoma currently has a difficult five-year survival rate of about 13 percent. Understanding how these tumors create local environments to evade immune destruction could lead to new, more effective therapies.
In a study published in Nature using the Perturb-map spatial genomics platform, researchers found that deleting PAI1 or PAI2 genes in mouse models reduced tumor burden by more than half. The study remains preliminary and focused on laboratory models.
The players
Icahn School of Medicine at Mount Sinai
An academic medical center that leads research into the biological mechanisms of cancer and therapeutic development.
The details
Pancreatic cancer cells express PAI1 and PAI2 proteins, which interfere with the enzymes that normally break down fibrin. By stabilizing these fibrin-rich barriers, just 5 percent of the cancer cells can effectively shield the entire tumor and recruit immune-suppressing macrophages. Targeting this pathway, when combined with anti-PD-1 therapy, appears to help immune cells penetrate the tumor microenvironment.
Timeline
September 9, 2026: The research findings were published in the journal Nature.
Health Landscape
This research follows a growing pattern of using tools like the Perturb-map spatial genomics platform to understand the tumor microenvironment. It shifts focus from attacking cancer cells alone to addressing the protective barriers they build within the body.
These findings are currently limited to laboratory and mouse studies and do not change existing treatment protocols for patients. Any questions about current immunotherapy options or clinical trials should be discussed with an oncologist.
The takeaway
Pancreatic tumors use specialized cells to create barriers that shield them from the immune system. Future clinical progress depends on proving these protective niches can be safely dismantled in humans.
Further reading
Learn more about the latest research and standard of care in the Cancer section.
More information
Review the full Nature study on pancreatic cancer for technical details.
Live Poll
Are you confident that new cancer research breakthroughs will lead to better survival outcomes soon?
